Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FABP4 | P15090 | 9/20 | 0.68 |
| ▸ | FABP5 | Q01469 | 9/20 | 0.68 |
| ▸ | FABP3 | P05413 | 6/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | GFER | P55789 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14917126 | 0.99 | FABP4 (0.67) | FABP4FABP5FABP3CYP2C9CYP2D6 | |
| SCHEMBL14927288 | 0.86 | FABP4 (0.70) | FABP4FABP5FABP3CYP2C9CYP2D6 | |
| SCHEMBL14927262 | 0.86 | FABP4 (0.51) | FABP4FABP5FABP3CYP2C9CYP2D6 | |
| SCHEMBL14927296 | 0.85 | FABP4 (0.51) | FABP4FABP5FABP3CYP2C9CYP2D6 | |
| SCHEMBL14916701 | 0.85 | FABP4 (0.70) | FABP4FABP5FABP3CYP2C9CYP2D6 | |
| SCHEMBL14927306 | 0.84 | FABP4 (0.49) | FABP4FABP5FABP3CYP2C9CYP2D6 | |
| SCHEMBL14916742 | 0.82 | FABP4 (0.48) | FABP4FABP5FABP3CYP2C9CYP2D6 | |
| SCHEMBL25334225 | 0.81 | FABP4 (1.00) | FABP4FABP5FABP3CYP2C9CYP2D6 | |
| SCHEMBL14927304 | 0.80 | FABP4 (0.45) | FABP4FABP5FABP3CYP2C9CYP2D6 | |
| SCHEMBL14917398 | 0.79 | FABP4 (0.52) | FABP4FABP5FABP3CYP2C9CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116761598-A | Antiviral use of FABP4 modulating compounds | 新月生物科学 | 2023-09-15 | — | — | CN | claimed |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-17 | — | — | US | claimed |
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-03 | — | — | US | claimed |
| EP-2773619-B1 | NEW ARYL-QUINOLINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2016-11-16 | — | — | EP | claimed |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | HOFFMANN-LA ROCHE INC. | 2016-03-03 | — | — | US | claimed |
| US-9199938-B2 | Aryl-quinoline derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-12-01 | — | — | US | claimed |
| EP-2773619-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | claimed |
| WO-2013064465-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | claimed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | claimed |
| US-12138243-B2 | Antiviral use of FABP4 modulating compounds | CRESCENTA BIOSCIENCES (US) | 2024-11-12 | — | — | US | disclosed |
| CN-116761598-A | Antiviral use of FABP4 modulating compounds | 新月生物科学 | 2023-09-15 | — | — | CN | disclosed |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | CRESCENTA BIOSCIENCES (US) | 2023-08-03 | — | — | US | disclosed |
| EP-4175647-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | Crescenta Biosciences (US) | 2023-05-10 | — | — | EP | disclosed |
| EP-2773619-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| WO-2013064465-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| WO-2013064465-A1 | NEW ARYL-QUINOLINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230241025-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | FABP4 2/4885FABP5 3/4885FABP3 4/4885 |
| US-20130116234-A1 | ARYL-QUINOLINE DERIVATIVES | FABP1, FABP4, FABP5 | FABP4 2/4885FABP5 3/4885FABP3 4/4885 |
| US-20160060270-A1 | New Aryl-Quinoline Derivatives | FABP1, FABP4, FABP5 | FABP4 2/4885FABP5 3/4885FABP3 5/4885 |
| US-12138243-B2 | Antiviral use of FABP4 modulating compounds | FABP1, FABP5, FABP4 | FABP4 3/4885FABP5 2/4885FABP3 4/4885 |
| US-20230255933-A1 | ANTIVIRAL USE OF FABP4 MODULATING COMPOUNDS | FABP1, FABP4, FABP5 | FABP4 2/4885FABP5 3/4885FABP3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.